Brief: Pfenex And NT Pharma Enter Into A Development And License Agreement For Pfenex's PF708 Therapeutic Equivalent Candidate To Forteo

China NT Pharma

18/04/2018 22:05

April 18 (Reuters) - China NT Pharma Group Co Ltd  1011.HK :
    * PFENEX AND NT PHARMA ENTER INTO A DEVELOPMENT AND LICENSE
AGREEMENT FOR PFENEX'S PF708 THERAPEUTIC EQUIVALENT CANDIDATE TO
FORTEO®
    * PFENEX INC - PFENEX RECEIVED A PAYMENT OF $2.5 MILLION
UPON
SIGNING OF AGREEMENT
    * PFENEX INC - PFENEX MAY BE ELIGIBLE TO RECEIVE ADDITIONAL
PAYMENTS OF UP TO $22.5 MILLION BASED ON ACHIEVEMENT OF
DEVELOPMENT,  SALES-RELATED MILESTONES
    * PFENEX INC - PFENEX MAY ALSO BE ELIGIBLE TO RECEIVE
DOUBLE-DIGIT
ROYALTIES ON NET PRODUCT SALES

Source text for Eikon:  ID:nPn2D4MXra 
Further company coverage:  1011.HK 

 ((Reuters.Briefs@thomsonreuters.com;))